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Introduction
The Breast Committee of the Arbeitsgemeinschaft 
Gynäkologische Onkologie (German Gynecological On-
cology Group, AGO) presents the 2021 update of the ev-
idence-based recommendations for the diagnosis and 
treatment of patients with early breast cancer (EBC) and 
metastatic breast cancer. This paper captures the update 
of EBC while the topics of metastatic breast cancer will be 
updated by Thill et al. The full version of the updated slide 
set including annotated speeches of each chapter is avail-
able online (www.ago-online.de/ago-kommissionen/
kommission-mamma) in English and German [1]. In ad-
dition, a version for patients is also available at www.ago-
online.de.
The AGO Breast Committee as an interdisciplinary 
team consists of specialists from gynecological oncology 
pathology, diagnostic radiology, medical oncology, and 
radiation oncology with a special focus on breast cancer. 
This update was performed according to a documented 
algorithm, by thoroughly reviewing and scoring chapter 
by chapter the most recent and relevant publications for 
their scientific validity (Oxford level of evidence [LoE], 
www.cebm.net) [2] and clinical relevance (AGO grades 
of recommendation [GR]) (Table 1).
Options for Primary Prevention and Lifestyle Factors
Individual risk factors can be classified into nonmodi-
fiable and modifiable lifestyle factors. Currently, there is 
good evidence that changes in some modifiable risk fac-
tors could substantially decrease individual breast cancer 
risk.
Relevant lifestyle factors such as obesity, alcohol con-
sumption (LoE 2a/B/AGO+), physical inactivity, fiber-
containing foods, smoking, and exposition to ionizing ra-
diation are well known. Adherence to normal body weight 
(BMI 18.5–25 kg/m2) as a preventive factor for the devel-
opment of breast cancer is well investigated particularly 
for postmenopausal women (LoE 2a/B/AGO++). For 
bariatric surgery, there is initial evidence for a reduction 
of breast cancer risk [3]. A Mediterranean diet including 
extra virgin olive oil (LoE 2b/B/AGO+), nuts (LoE 2b/B/
AGO+) (>10 g/day), and reduced consumption of fat 
(LoE 2a/B/AGO+) and red meat may decrease the inci-
dence of breast cancer. For other factors such as supple-
mentation of vitamin D3, vegetarian or vegan diet, vege-
tables, fruits, or phytoestrogens there are yet insufficient 
or contradictory data regarding the reduction of breast 
cancer incidence. In contrast, physical exercise (metabol-
ic equivalents to 3–5 h of moderate-pace walking per 
week) has been demonstrated to be efficient in reducing 
breast cancer risk (LoE 2a/B/AGO++).
Avoidance of hormone replacement therapy (especial-
ly estrogen/progestin combination regimens) in post-
menopausal women may reduce breast cancer risk (LoE 
1b/A/AGO+). Oral contraceptives do not increase the 
probability of death from breast cancer (LoE 1a).
Regarding chemopreventive agents other than endo-
crine therapy, the effect of acetylsalicylic acid [4], bisphos-
phonates [5], and statins has been evaluated. Some en-
couraging results suggest that acetylsalicylic acid use 
might reduce breast cancer risk, particularly regarding 
hormone receptor (HR)-positive or in situ breast tumors, 
in postmenopausal women (LoE 4D/D/AGO+/–). 
Bisphosphonates are rated LoE 2b/B/AGO+/– for prima-
ry prevention of breast cancer. No risk-reducing effect on 
breast cancer risk was shown for statins.
Breast Cancer Risk and Prevention
The AGO Mamma still recommends genetic counsel-
ing and testing based on individual and family history. 
General testing of all breast cancer patients is not recom-
mended as expansion of testing criteria would result only 
in a slightly higher detection of BRCA1/2 mutations in 
about 0.7% but also in a higher detection of other muta-
tions with no evidence-based clinical action [6], increas-
ing the risk of overtreatment. However, there is evidence 
to suggest that the PARP inhibitor olaparib is effective in 
PALB2 mutation carriers as well as in patients with so-
matic BRCA1/2 mutation [7]. New evidence with gene 
mutation analysis in 113,000 women proved that muta-
tions in BRCA1/2 and PALB2 were associated with high 
breast cancer risk (LoE 1b/A/AGO++) and ATM, 
BARD1, CHEK2, RAD 51C, and RAD 51D with moder-
ate breast cancer risk (LoE 1b/B/AGO+) [8]. PALB2 mu-
tation resulted in a lifetime risk for breast cancer almost 
as high as BRCA2 mutation. Interestingly, the relevance 
of prostate cancer screening in BRCA2 mutation carriers 
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is unknown and currently investigated in the Impact 
Trial.
There is still controversy as to the role of breast-con-
serving surgery (BCS) and mastectomy for BRCA1/2 mu-
tation carriers. Overall, no randomized controlled trial 
has yet been published. However, one prospectively col-
lected clinical cohort demonstrated that contralateral 
breast cancer risk was higher for mutation carriers (24.4% 
for BRCA1 carriers, 20% for BRCA2 carriers, and 9% for 
noncarriers), but, interestingly, the ipsilateral in-breast 
recurrence risk was lower (8.7% for BRCA1, 14.1% for 
BRCA2, and 20% for noncarriers) [9]. No trial showed a 
difference in disease-free survival (DFS) according to sur-
gical method [10]. Breast-conserving therapy was not as-
sociated with adverse short- or long-term survival out-
comes. Therefore, breast-conserving therapy should be 
offered as an option to BRCA mutation carriers (LoE 
2a/B/AGO+) provided proper preoperative counseling 
(LoE 5/D/AGO++).
Breast Cancer Diagnostics
In asymptomatic women, screening mammography 
(MG) is recommended for women 50–69 years of age 
(LoE 1a/A/AGO++). For women aged from 40 to 44 
screening is not recommended (LoE 1b/B/AGO–), and 
from 45 to 49 individual shared decision-making is rec-
ommended and clear indication is necessary (LoE 1a/B/
AGO+). Above 75 years of age screening can be offered 
to women in good health with a life expectancy of 10 years 
or longer (LoE 4/C/AGO+/–) [11].
Breast density is a known risk factor for breast cancer 
development and decreased MG sensitivity. Neverthe-
less, neither use of hand-held US nor automated whole-
breast US can be recommended as a sole modality for 
screening (LoE 3a/C/AGO–) [11]. Using digital breast to-
mosynthesis the recall and biopsy rates were low (LoE 
1a/B/AGO+) [12]. Synthetic 2D image reconstruction of 
the 3D dataset can significantly reduce radiation dose and 
is highly recommended (LoE 2a/B/AGO++). Neverthe-
less, it is very important to use the complete dataset for 
diagnosis and provide it for the subsequent treatment 
[13]. In a recent randomized controlled trial, MRI in the 
extremely dense breast screening group with negative 
MG showed a significantly reduced interval cancer rate at 
the cost of slightly increased false-positive cases (LoE 
1b/B/AGO+) [14].
For patients with breast symptoms, clinical examina-
tion (LoE 3b/B/AGO++), MG (LoE 1b/A/AGO++), digi-
tal breast tomosynthesis (LoE 2b/B/AGO+) or contrast-
enhanced MG (LoE 2a/B/AGO+), US (LoE 2b/B/
AGO++), and minimally invasive biopsies (LoE 1c/A/
AGO++) should be performed [15].
As part of surgical planning, MRI can be helpful for 
patients with a reduced sensitivity of MG and US, nipple 
involvement, lobular invasive cancer, suspicion of multi-
locular disease, and/or high risk (LoE 1b/B/AGO+), pro-
vided that MRI-guided vacuum-assisted biopsy access is 
available in-house or among cooperating partners [16]. 
Second-look US is recommended in cases of lesions de-
tected by MRI only.
In patients with clinically and/or sonographically sus-
picious axillary lymph nodes, core needle biopsy is rec-
ommended (LoE 2b/B/AGO++). If biopsy reveals lymph 
node involvement prior to neoadjuvant therapy, a clip 
should be inserted in the lymph node after biopsy to allow 
targeted axillary dissection (TAD) at the time of surgery.
Staging is recommended for candidates scheduled for 
(neo)adjuvant chemotherapy including CT (chest/abdo-
men) and bone scans (LoE 2b/B/AGO+). PET-CT should 
be reserved for individual cases with high-stage (III) can-
cer (LoE 2b/B/AGO+/–).
Pathology
Established immune markers still preserve their rele-
vance for clinical decision-making in breast cancer treat-
ment with even extended meanings. Estrogen receptor 
Table 1. AGO grades of recommendation
++ This investigation or therapeutic intervention is highly beneficial for patients, can be recommended without 
restrictions, and should be performed
+ This investigation or therapeutic intervention is of limited benefit for patients and can be performed
+/– This investigation or therapeutic intervention has not shown benefit for patients and may be performed only in 
individual cases; according to current knowledge a general recommendation cannot be given
– This investigation or therapeutic intervention can be of disadvantage for patients and might not be performed
–– This investigation or therapeutic intervention is of clear disadvantage for patients and should be avoided or omitted in 
any case
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(ER) level should not only be categorized in positive or 
negative. Low ER levels ≤10% of labeled cells needs to be 
handled differently (LoE 1a/A/AGO++). Tumors with 
low ER levels are more similar to triple-negative breast 
cancer (TNBC) than to luminal tumors in terms of their 
gene expression profiles and frequency of BRCA1/2 
germline mutations. Different thresholds to define this 
subgroup have been applied with ≤10% being the most 
widely used [17]. Another relevant marker is Ki-67. Ki-67 
response (i.e., Ki-67 ≤10%) after short-term endocrine 
therapy before surgery can be used to assess endocrine 
responsiveness (LoE 1b/A/AGO+), based on the POETIC 
[18] and the ADAPT trial results [19].
Recently, it has been shown that in neoadjuvant endo-
crine therapy (NET) the drop of Ki-67 levels might iden-
tify responders after short-term endocrine preoperative 
therapy (LoE 1b/B/AGO+) [20]. The addition of a novel 
immune marker like the checkpoint inhibitor atezoli-
zumab or pembrolizumab to chemotherapy showed first 
promising results regarding pathological complete re-
sponse (pCR) [21–23, 47].
Lesions of Uncertain Malignant Potential (B3)
Lesions of uncertain malignant potential (B3) are usu-
ally detected by core or vacuum-assisted biopsy in asymp-
tomatic women. The risk of developing invasive cancer 
associated with B3 lesions can be categorized according 
to the type of lesion (atypical ductal hyperplasia, flat epi-
thelial atypia, lobular intraepithelial neoplasia, papillo-
ma, radial scar) in addition to clinical and pathological 
factors. The indication for complete surgical excision of 
B3 lesions is to exclude any upstaging of more severe pre-
cursor lesions (ductal carcinoma in situ [DCIS]) or inva-
sive lesions.
Atypical ductal hyperplasia has a particularly high risk 
of being associated with breast cancer when combined 
with BIRADS IV/V and high breast tissue volume. In fact, 
atypical ductal hyperplasia on core biopsy may represent 
inadequately sampled DCIS.
In cases of biopsy of classical lobular intraepithelial 
neoplasia, open excision can be avoided if no discordant 
imaging, especially no focal lesion, is present [24]. In con-
trast, high-risk variants of lobular neoplasia, which in-
clude pleomorphic and florid lobular carcinoma in situ, 
are recommended for open biopsy and preferably com-
plete excision.
The diagnosis of solitary or multiple papillomas on 
core biopsy might be associated with an increased risk of 
30% (with atypia) for an invasive carcinoma or DCIS [25].
A radial scar may mimic carcinoma mammographi-
cally because of its stellate appearance. Radial sclerosing 
lesions are only rarely associated with atypia or DCIS. 
When radial scar is associated with atypia (such as flat 
epithelial atypia, atypical ductal hyperplasia, or classical 
lobular intraepithelial neoplasia), management can be 
similar to atypia alone [26].
Medical prevention (e.g., low-dose tamoxifen [LoE 
2b/B/AGO+/–]) for lesions with uncertain biological be-
havior may be performed only in individual cases [27].
Prognostic and Predictive Factors
Locoregional tumor burden together with tumor biol-
ogy are the major prognostic drivers and the key determi-
nants of therapy decisions in EBC. In luminal EBC, clini-
cal algorithms such as Predict (https://breast.predict.nhs.
uk) can be used to estimate prognosis (LoE 1b/A/AGO+). 
For lobular EBC, tumor size, nodal status, and lymphovas-
cular invasion constitute a point-based risk score that can 
help to identify high-risk disease [28] (LoE 2b/B/AGO+/–). 
Histological type, however, should not be used as a sole 
criterion for chemotherapy decision-making (AGO–).
Gene expression assays (LoE 1b/A: Oncotype DX, 
MammaPrint; LoE 2b/B: EndoPredict, Prosigna) can be 
used in luminal EBC with 0–3 involved lymph nodes for 
indicating the use of chemotherapy if the use of routine 
prognostic factors is not conclusive (AGO+). The deci-
sion to omit chemotherapy needs to be based on the re-
spective evidence for the test used. In premenopausal pa-
tients, different cutoff values or different thresholds for 
omitting chemotherapy may need to be applied com-
pared to postmenopausal patients. The results should be 
discussed with the patients not just in terms of prognosis, 
but also in terms of absolute gain by adjuvant chemother-
apy for DFS and overall survival (OS), including short- 
and long-term side effects and toxicities.
Ductal Carcinoma in situ
DCIS accounts for approximately 20% of all breast 
cancers in a screening population. MG is the main tool 
used for diagnosis of DCIS. Breast MRI may be helpful for 
assessment of the extension and surgical planning of 
DCIS (LoE 1b/B/AGO+/–), but can lead to over- and un-
derestimations of the extension of the DCIS as it repre-
sents an extremely heterogeneous group of lesions with 
variable potential for progression to invasive disease [29]. 
Complete surgical excision is the standard of care (LoE 
1a/A/AGO++). BCS is recommended. Almost all guide-
lines recommend clear margins of 2 mm for pure DCIS. 
Sentinel lymph node biopsy might be recommended in 
rare cases when the surgical procedure is not allowing a 
sentinel lymph node in case of an upstaging into invasive 
cancer (i.e., cases of mastectomy, LoE 3b/B/AGO+).
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Radiotherapy is recommended after BCS of DCIS 
(LoE 1a/A/AGO++). Patients should be informed that 
the absolute (individual) benefit of radiotherapy depends 
on the individual risk of local recurrence and that avail-
able data do not impact survival. In the multicenter, ran-
domized, unblinded BIG 3-07/TROG 07.01 trial, among 
1,608 patients hypofractionated whole-breast irradiation 
presented a HR of 0.94 (95% CI 0.51–1.74) for local re-
currence-free survival and a HR of 0.79 (95% CI 0.48–
1.32) for DFS. By this, conventional fractionated radio-
therapy (50 Gy in 25 fractions) (LoE 1a/A/AGO+) or hy-
pofractionated radiotherapy (40–42.5 Gy in 15–16 
fractions) are equal options (LoE 1a/A/AGO+) [30]. A 
boost should only be considered on an individual basis in 
case of further risk factors (LoE 1ba/B/AGO+/–). Partial 
breast irradiation can be considered in cases aged ≥50 
years, DCIS ≤3 cm, G1–2, R0 (≥5 mm) and unifocal/uni-
centric DCIS (LoE 1b/B/AGO+) [31].
Regarding systemic treatment, patients should be in-
formed that adjuvant endocrine treatment has no impact 
on survival (LoE 1a), but may have a small effect on ipsi-
lateral invasive and DCIS recurrences and on contralat-
eral invasive and noninvasive cancer (LoE 1a). The ongo-
ing discussion whether tamoxifen or anastrozole is more 
effective was answered by current results of the IBIS-II 
DCIS trial [32]. After a median follow-up of 11.6 years, 
there was no difference in breast cancer recurrences (HR 
0.89 [95% CI 0.69–1.16], p = 0.401), but more endome-
trial (OR 0.17, p = 0.0086) and ovarian cancers (OR 0.13, 
p = 0.022) with tamoxifen and more strokes (OR 3.10, 
p = 0.021) and transient ischemic attacks (OR 3.10, p = 
0.021) with anastrozole. By this, both therapies may be 
considered on an individual basis depending on risk fac-
tors, side effects, and patient preference (AGO+/–).
Breast Cancer Surgery under Oncological Aspects
Surgery is part of the multidisciplinary therapeutic ap-
proach in EBC. Avoidance of a significant delay of 4 
weeks or more in cancer treatment is recommended 
(AGO+) because of its strong prognostic influence. Wire-
less intraoperative US localization may serve as an excel-
lent method for tumor detection in BCS (LoE 2b/B/
AGO++) [33].
For breast surgery “no ink on tumor” remains the ac-
cepted standard for clear margins for all patients (pro-
vided that all suspicious lesions according to preoperative 
imaging are resected [LoE 2a/A/AGO++]). BCS is also an 
option for patients with multifocal and multicentric dis-
ease when R0 resection is confirmed (LoE 2b/B/AGO+). 
Sentinel lymph node excision (SLNE) is the standard of 
care staging procedure of the ipsilateral axilla in patients 
with invasive disease and unsuspected nodes (cN0) (LoE 
1b/A/AGO++). Suspicious lymph nodes should be evalu-
ated by core needle biopsy and clip placement. This is 
mainly due to the American College of Surgeons Oncol-
ogy Group (ACOSOG) Z0011 trial, confirmed by 10-year 
follow-up [34], and the AMAROS trial [35] as well as con-
firming studies with no differences in locoregional con-
trol, DFS, or OS.
Following neoadjuvant therapy SLNE should be per-
formed after neoadjuvant chemotherapy (NACT) as it re-
duces the rate of axillary lymph node dissection (ALND) 
(ycN0 after cN0) and axillary remission provides addi-
tional prognostic information (LoE 2b/B/AGO++). In 
patients with a clinically negative axilla (cN0) before 
NACT and tumor-infiltrated sentinel lymph node after 
NACT (including micrometastases), a full ALND should 
be performed (LoE 2bB/AGO+) [36].
For patients who initially presented with (core needle 
biopsy-proven) positive axillary lymph nodes (pN+) and 
who converted to ycN0 after NACT, the accuracy of SLNE 
is lower than in the adjuvant setting [37]. Since unselected 
axillary sampling is not indicated and ALND may be 
harmful, TAD offers an alternative in these patients (LoE 
2bB/AGO+). TAD implies the combination of SLNE and 
removal of the core needle biopsy-positive target lymph 
node (TLNE) marked with a clip, coil, seed, or tattoo. Cau-
dle et al. [38] described a significant reduction in false-
negative rate from 10.1% with SLNE alone to 4.2% with 
TLNE alone, and 1.4% in case of combination of SLNE 
and TLNE (TAD). The impact of TAD on DFS is still un-
known. In case of residual tumor burden (ypN1) after 
TAD, ALND is recommended (AGO++); in case of only 
residual isolated tumor cells, the therapeutic consequence 
is still unclear and has to be specified in accordance with 
the results of ongoing studies (e.g., AXSANA trial).
Oncoplastic and Reconstructive Surgery
Oncoplastic surgery is an essential component in the 
treatment strategy for breast cancer patients [39]. It is de-
fined as the use of simultaneous reconstructive tech-
niques during breast cancer surgery offering an optimal 
outcome optimizing quality of life without any compro-
mises towards oncological safety. Oncoplastic surgery fo-
cuses on optimized scar positioning, adequate soft tissue 
shaping, the choice of a suitable reconstruction proce-
dure, and reconstruction of the contralateral breast in or-
der to achieve symmetry. Valid evidence is lacking for the 
majority of important questions. For implant-based re-
construction, pre- and subpectoral implant placement 
with or without additional devices (either synthetic or au-
tologous like acelluar dermal matrices) can be performed. 
Participation in studies to evaluate these procedures 
should be supported [40].
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Perioperative systemic antibiotic prophylaxis for im-
plant-based reconstruction is recommended to be per-
formed not longer than 24 h (LoE 2a/B/AGO+), and top-
ical antibiotics/antiseptics should be used frequently as 
surgical site infection can be decreased significantly when 
compared to no topical antibiotics (LoE 2a/B/AGO+); 
moreover, it reduces the rate of capsular contraction [41].
Regarding prevention of capsular contraction, there is 
good evidence for textured implants (LoE 1a/A/AGO+) 
and the use of acellular dermal matrices (LoE 2a/B/
AGO+) [42] and synthetic meshes (LoE 3a/C/AGO+) 
when compared to nothing. Povidone-iodine has become 
an option again (LoE 2a/B/AGO+/–). Use of leukotriene 
antagonists (LoE 2a/B/AGO–) still has limited data re-
garding their long-term toxicity; no benefit is seen when 
breast massage is performed (LoE 3a/C/AGO–). In cases 
of presence of capsular contraction, capsulectomy and 
capsulotomy have old but consistent data (LoE 3b/C/
AGO+). If using textured implants or performing capsu-
lectomy/capsulotomy, one has to be aware of breast im-
plant-associated anaplastic large-cell lymphoma that rep-
resents a rare malignant disease after implantation of a 
breast implant, which usually occurs with textured im-
plants.
Therapy of persistent seroma after implant-based re-
construction is lacking robust data. Evacuation of seroma 
and reinsertion of drainage can be performed and revi-
sion surgery with capsulectomy or implant removal is 
recommended as ultima ratio (LoE 5/D/AGO+). There is 
no consensus for the duration of drains, but the consis-
tent data are in favor of drain removal at <30 mL/24 h 
(LoE 2b/B/AGO+) [43].
Neoadjuvant Chemotherapy
If chemotherapy is indicated in patients with EBC, 
NACT should be preferred. For patients with increased 
risk of recurrence, dose-dense chemotherapy schedules 
are recommended, including weekly taxane regimens 
(AGO++). Based on current data, a higher pCR rate and 
improved DFS can be achieved by use of nab-paclitaxel 
compared to solvent-based paclitaxel (HR+, TNBC) (LoE 
1b/B/AGO+) [33, 44–46]. In patients with HER2-positive 
tumors, anthracycline- and taxane-based or anthracy-
cline-free regimen with carboplatin (both AGO++) and 
trastuzumab (in patients with N+ plus pertuzumab 
[AGO++]) are recommended. In TNBC, dose-dense che-
motherapy with anthracyclines including weekly taxanes 
is the current treatment standard. The addition of plati-
num is possible, irrespective of BRCA mutation status 
(AGO+). Due to significantly increased pCR rates in two 
neoadjuvant trials, the use of neoadjuvant systemic ther-
apy (NAST) in combination with immune checkpoint in-
hibitors including pembrolizumab (Keynote 522 trial) 
[47] or atezolizumab (IMpassion031 trial) [48] indepen-
dent from PDL1 status is a new option preferably within 
clinical trials (LoE 1b/B/AGO+/–).
Neoadjuvant Endocrine Therapy
NET is suitable for patients who are inoperable or not 
able or willing to undergo chemotherapy. Selection of en-
docrine treatment should be based on the menopausal 
status and given for at least 4–6 months. NET for 2–4 
weeks might be used for prognostic evaluation in oder to 
predict the efficacy of endocrine treatment by the course 
of Ki-67 changes.
Post-Neadjuvant Therapy Options – AGO 
Recommendations
For patients with HR-positive EBC, endocrine therapy 
according to menopausal status is the standard of care. In 
the monarchE trial (abemaciclib), in contrast to the PAL-
LAS and PENELOPE-B study (both with palbociclib), the 
addition of abemaciclib to standard endocrine treatment 
resulted in an improved 2-year invasive disease-free sur-
vival (IDFS) with the caveat of a short follow-up of 19 
months. Currently, this option should only be offered 
within clinical trials (only LoE 2b/B/AGO+/–) [49–51].
Capecitabine is recommended in patients with TNBC 
and no pCR (LoE 2b/B/AGO+). Patients should be en-
couraged to participate in clinical trials evaluating exper-
imental postneoadjuvant therapies (AGO+).
Patients who did not achieve pCR should receive 14 
cycles of T-DM1 after NAST (LoE 1b/B/AGO+). Based 
on the results of the ExteNET trial showing a significant-
ly improved DFS rate, escalation of HER2-targeted ther-
apy with neratinib in addition to standard endocrine 
therapy can be offered to HR-positive patients who have 
received the last trastuzumab dose within 12 months [52] 
(LoE 2b/B/AGO+/–).
In patients with pCR after optimal NAST, continua-
tion of the initiated anti-HER2 therapy is recommended 
up to completion of 1 year. In patients with pCR and low 
risk of recurrence, de-escalation to trastuzumab mono-
therapy is recommended (LoE 2a/C/AGO++).
Adjuvant Cytotoxic and Targeted Therapy
Adjuvant anthracycline- and taxane-based chemo-
therapy reduces breast cancer mortality by approximate-
ly one-third, depending on the absolute risk of recurrence 
[53].
Very recently, a patient-level meta-analysis demon-
strated that increasing the dose intensity of chemothera-
py by more frequent administration or sequential sched-
uling moderately improved the 10-year risk of recur-
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rence and death from breast cancer [54]. Therefore, 
dose-dense chemotherapy (LoE 1a/A/AGO++) instead 
of conventionally dosed anthracycline- and taxane-based 
chemotherapy (q3w) (LoE 1/A/AGO+) should be the 
preferred treatment option. In patients with high risk of 
recurrence (i.e., ≥4 involved axillary lymph nodes), dose-
dense and dose-intensified chemotherapy demonstrated 
superior survival compared with a conventional sched-
ule, especially in high-risk HR-positive patients [55]. 
Most strikingly, OS was improved with an absolute dif-
ference of 10% after 10 years of follow-up (LoE 1/A/
AGO++).
As shown in a meta-analysis, only patients with TNBC 
and non-pCR after optimal NAST might have a benefit 
from the addition of capecitabine (LoE 1aa/A/AGO+). 
Thus, general use in TNBC cannot be recommended 
(LoE 1aa/A/AGO–) [56]. In TNBC, the question of add-
ing carboplatin as a fourth substance has still not been 
finally clarified with regard to an OS advantage [57]. 
However, if an anthracycline-free therapy is chosen, a 
taxane/platinum combination should be used here (LoE 
1b/B/AGO+) [58]. In patients with reduced left ventricu-
lar ejection fraction, anthracycline-free therapy with 
docetaxel/cyclophosphamide (LoE 1b/B/AGO+) might 
be an option, while other regimes like weekly paclitaxel 
(LoE 1b/B/AGO+/–) or CMF (LoE 1a/A/AGO+/–) may 
not be sufficiently effective. In patients with TNBC tu-
mors and negative lymph nodes, the AGO recommends 
adjuvant chemotherapy for tumors of 5–10 mm, while for 
tumors <0.5 cm there is no indication for adjuvant che-
motherapy (LoE 2b/B/AGO–).
In patients with HER2-positive EBC, anti-HER2 ther-
apy with trastuzumab is highly recommended (LoE 
1a/A/AGO++). Trastuzumab might be either combined 
with an anthracycline- and taxane-based chemotherapy 
(LoE 1a/A/AGO++) or an anthracycline-free regimen 
like carboplatin/docetaxel (LoE 1b/A/AGO++). In pa-
tients with HER2-positive node-negative EBC with a 
maximum diameter of 2 cm, trastuzumab might be com-
bined with weekly paclitaxel (LoE 2b/B/AGO+). Based 
on the updated follow-up of the APT trial, patients with 
node-negative EBC treated with this de-escalating regi-
men had an excellent 7-year IDFS of 93%. The updated 
analysis of the APHINITY trial support adjuvant pertu-
zumab in addition to trastuzumab and chemotherapy 
only in patients with node-positive disease with HER2-
positive EBC (LoE 1ba/B/AGO+). At a median follow-up 
of 74.1 months IDFS in node-positive patients was 87.9% 
for trastuzumab and pertuzumab versus 83.4% for trastu-
zumab. In the node-negative cohort, no additional clini-
cal benefit was evident for the dual blockade (LoE 1ba/B/
AGO+/–).
For extended adjuvant treatment (EAT), the tyrosine 
kinase inhibitor neratinib in combination with standard 
endocrine treatment for 12 months may be an option for 
HR-positive patients who have completed 1 year of trastu-
zumab-based therapy (LoE 1b/B/AGO+).
Adjuvant Endocrine Therapy
Endocrine therapy is indicated in all patients with HR-
positive EBC (LoE 1/A/AGO++). A meta-analysis of the 
German Breast Group of several neoadjuvant trials suggests 
that tumors with low HR expression (≥1–9%) are biologi-
cally similar to TNBC. Thus, omitting endocrine therapy 
may be an option in cases with very low expression of ER 
and progesterone receptor (PR) (LoE 1/A/AGO++) [59]. In 
case of ER–/PR+ (>10%), immunohistochemical re-evalu-
ation of ER should be performed. False positivity for PR 
should be excluded [60]. A treatment duration of 5 years 
remains the standard of care. EAT might be indicated in 
patients with increased risk of relapse, such as GIII or node-
positive disease at presentation.
Premenopausal Patients
The SOFT and TEXT trials are providing the most rel-
evant evidence for treatment recommendations in pre-
menopausal patients [61]. Patients with a low risk of re-
currence might be treated with tamoxifen (LoE 1a/A/
AGO++), patients with an intermediate recurrence risk 
should be offered ovarian function suppression in addi-
tion to tamoxifen (LoE 2b/C/AGO++), and in patients 
with a high risk of recurrence risk the use of aromatase 
inhibitors (AIs) and ovarian function suppression (for 5 
years) (LoE 1b/B/AGO+) might be the best option. All 
other statements from 2020 are still valid.
Postmenopausal Patients
Interestingly the recommendations from 2020 have 
not been changed. With regard to the adjuvant use of 
CDK4/6 inhibitors, three studies have been published 
(PENELOPE-B, PALLAS, and monarchE) [62–64]. But 
none of these drugs have a label in the adjuvant setting yet.
EAT in Premenopausal Women
Tamoxifen can be extended for up to 10 years (LoE 
1a/A/AGO++). EAT with 5 years of tamoxifen should 
also be offered to those patients with ovarian suppression 
and tamoxifen or an AI for their initial treatment (LoE 
5/D/AGO+). If the patient is confirmed as being post-
menopausal within the first 5 years, endocrine therapy 
can be continued after 5 years of tamoxifen with 2.5–5 
years of letrozole (LoE 1b/B/AGO+).
EAT in Postmenopausal Women
After 5 years of tamoxifen, extended therapy with 5 
years of tamoxifen is still an option (LoE 1a/A/AGO+), 
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but switching to an AI for 2–5 years should be preferred 
(LoE 1a/A/AGO++). If patients received an AI (upfront 
or switch), patients at higher risk should be offered 2–5 
additional years of AI (LoE 1b/B/AGO+).
Adjuvant Radiotherapy
Moderately hypofractionated whole-breast radiother-
apy remains the standard of care for the majority of pa-
tients after BCS (LoE 1a/A/AGO++). Ultra-hypofraction-
ated whole-breast irradiation in five fractions over 1 or 5 
weeks according to the FAST [65] and FAST-Forward 
[66] trials may be used in selected cases (LoE 1b/B/
AGO+/–). A tumor bed boost is routinely recommended 
in premenopausal patients (LoE 1b/B/AGO++) and 
should be used in a risk-adapted manner in postmeno-
pausal patients (LoE 2b/B/AGO+). If using convention-
ally fractionated whole-breast radiotherapy, the use of a 
simultaneous integrated boost is feasible, as shown by two 
recent randomized controlled trials (LoE 1b/B/AGO+) 
[67, 68]. Partial breast irradiation with interstitial brachy-
therapy, intensity-modulated radiotherapy over one-and-
a-half weeks, or 3D conformal radiotherapy over 3 weeks 
are viable options for patients with early-stage, low-risk 
breast cancer (LoE 1a/A/AGO+). Intraoperative radio-
therapy such as partial breast irradiation should preferen-
tially be used in patients aged >70 years (LoE 1b/A/AGO+; 
LoE 1b/A/AGO+/– for patients >50 years). Recommen-
dations regarding post-mastectomy radiotherapy and re-
gional nodal irradiation to the supra-/infraclavicular and 
the internal mammary lymphatics remain unchanged. Ra-
diotherapy to the axilla (level I/II in addition to whole-
breast or post-mastectomy radiotherapy) should be per-
formed in patients who do not fulfil the ACOSOG Z0011 
criteria and did not undergo ALND (LoE 1b/B/AGO++). 
After ALND, radiotherapy to the axilla should only be 
performed in case of macroscopic residual disease (LoE 
5/D/AGO++). After NACT, patients with ypN1mic(sn/
TAD) or ypN+(sn/TAD) who did not undergo ALND 
should receive radiotherapy to the axilla (LoE 5/D/AGO+). 
Patients with clinically positive lymph nodes who convert 
to ypN0(sn/TAD) after NACT may receive additional ra-
diotherapy to the axilla (LoE 5/D/AGO+/–). If CDK4/6 
inhibitors are used in the adjuvant setting, treatment may 
be given sequentially with adjuvant radiotherapy, as in the 
relevant phase III trials (LoE 4/C/AGO+/–).
Breast Cancer: Special Situations
While tamoxifen remains the standard for endocrine 
treatment of male breast cancer, some evidence also exists 
for use of AIs and fulvestrant. There are very limited data 
supporting the use of CDK4/6 inhibitors among male pa-
tients with breast cancer [69]. However, the FDA has re-
cently expanded the approved indications to include 
men. Based on this, the AGO recommends the use of 
CDK4/6 inhibitors for male patients with advanced/met-
astatic breast cancer (LoE 2b/B/AGO+).
The indications for mastectomy after NACT remain 
unchanged: positive margins after repeated excisions 
(LoE 3b/C/AGO++), lack of feasibility of radiotherapy 
(LoE 5/D/AGO++), and presence of inflammatory breast 
cancer (with no more than clinical complete response) 
(LoE 2b/C/AGO+/–) [70].
Phyllodes tumors are classified as benign, borderline, 
and malignant, with varying risk of local recurrence. Re-
cently, it has been shown that narrow margins for phyl-
lodes tumors are not associated with an increased risk of 
local recurrence, and it was proposed that a negative mar-
gin may not be necessary for benign phyllodes tumors 
[71]. Therefore, the AGO has agreed to revise the mini-
mal resection margins required for borderline and malig-
nant phyllodes tumors, and a resection margin of 1 mm 
is now considered sufficient (LoE 2b/B/AGO++).
Metaplastic breast carcinoma must be distinguished 
into the commonly observed high-grade metaplastic car-
cinoma and the rare forms of metaplastic carcinoma with 
uncertain malignant potential (fibromatous-like and ad-
enosquamous carcinoma). Typically, metaplastic breast 
carcinomas are malignancies with triple-negative im-
mune phenotype, but their prognostic and therapeutic 
implications differ from usual TNBC [72]. They tend to 
be rather chemoresistant, and this must be considered for 
planning adjuvant therapy or NACT. Operative therapy, 
axillary staging, and adjuvant radiotherapy should be 
performed according to the standard (LoE 4/C/AGO++) 
for high-grade tumors. However, for low-grade – fibro-
matous-like and adenosquamous – metaplastic carcino-
mas, no benefit of adjuvant (LoE 4/C/AGO–) or neoad-
juvant (LoE 4/C/AGO–) chemotherapy can be expected, 
because these are considered to be tumors of uncertain 
malignant potential [73].
Complementary Therapy and Survivorship
Recently published studies and review articles under-
line the effects of physical exercise (endurance training 
three times a week in combination with workout exer-
cises two times a week) on quality of life, cardiorespira-
tory fitness, physical performance, sleep, pain, depres-
sion, lymphedema, and fatigue (LoE 1a/A/AGO++). Evi-
dence is growing that mind-body interventions (including 
cognitive therapies, behavioral therapies, relaxation tech-
niques, and meditation) improve quality of life among 
breast cancer patients, and therefore clinical guidelines 
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have begun to include recommendations. A systemic re-
view and meta-analysis of 19 randomized controlled tri-
als (n = 2,806) revealed evidence that mind-body inter-
ventions are efficacious for reducing fear of cancer recur-
rence, although further investigations are recommended 
to analyze the optimal integration of mind-body prac-
tices (LoE 1a/A/AGO+).
Acupuncture can improve chemotherapy-induced 
nausea and vomiting, cancer pain, fatigue, menopause 
syndrome, anxiety and depression, as well as AI-induced 
arthralgia (AGO+).
Gynecological Issues in Breast Cancer Patients and 
Contraception
Systemic hormone replacement therapy to alleviate 
menopausal symptoms is contraindicated in breast can-
cer patients (LoE 1b/B/AGO–), while topical vaginal ap-
plication of low-dose estriol may be used for urogenital 
symptoms (LoE 4/D/AGO+/–). Hot flushes may be treat-
ed with serotonin reuptake inhibitors (i.e., venlafaxine) 
(LoE 1a/A/AGO+). A recent study found that 2.5 or 
5.0 mg oxybutynin twice a day for 6 weeks was an effec-
tive treatment option for women with hot flushes [74] 
(LoE 1b/A/AGO+/–). Homeopathy and phytotherapy 
had no effect on hot flushes in large randomized trials 
compared with placebo in breast cancer survivors (LoE 
1b/B/AGO–) [75]; interestingly, in these studies a sub-
stantial effect was observed also in the control arm (“pla-
cebo effect”). Sleep disturbances might be treated with 
melatonin (LoE 2b/C/AGO+).
Physical exercise has positive effects on menopausal 
symptoms and, to a lesser degree, on the sexuality of pa-
tients experiencing treatment-induced menopause (LoE 
1a/A/AGO++) [76]. Cognitive behavioral therapy is effec-
tive in alleviating treatment-induced menopausal symp-
toms (LoE 1b/B/AGO++). Mind-body medicine results in 
a moderate improvement in hot flushes scores, joint pain, 
fatigue, and sleep (LoE 1b/B/AGO+). There are contradic-
tory data about the effect of acupuncture on hot flushes, 
depression, and sleep disturbances, but it can be used to 
treat AI-induced joint pain (LoE 1b/B/AGO+) [77].
Fertility counseling on fertility preservation (https://
fertiprotekt.com) should be offered to all patients who 
wish to retain their fertility (AGO++). Application of go-
nadotropin-releasing hormone analogs >2 weeks prior 
chemotherapy has shown an improved rate of recovery of 
ovarian function after 2 years (LoE 1a/B/AGO+) and 
might have a moderate effect on preservation of fertility 
(LoE 2a/B/AGO+/–). Low anti-Müllerian hormone levels 
seem to be indicative of reduced ovarian reserve in che-
motherapy-treated breast cancer patients (LoE 1b/B/
AGO+).
Hormone-free contraceptive methods are the first 
choice for patients with breast cancer.
Sexual complaints are common in breast cancer pa-
tients and should be assessed. Screening tools may help 
physicians to address sexual health issues (LoE 4/C/
AGO+). Nonhormonal lubricants and moisturizers are 
the primary treatment for vaginal dryness and dyspareu-
nia (LoE 1b/B/AGO+). Microablative fractionated laser 
or vaginal YAG/erbium laser may be an option for some 
patients to alleviate genital atrophy (LoE 2a/A/AGO+/–) 
[78].
Breast Cancer: Supportive Care and Side Effect 
Management
Optimal side effect management and supportive care 
are major contributors to the overall risk/benefit balance 
associated with oncological therapies. This chapter of the 
AGO recommendations details aspects that are particu-
larly relevant for the treatment of breast cancer patients 
and is based on the most recent version of the S3 guide-
lines [79] as well as other international guidelines such as 
those of the ESMO wherever available.
Chemotherapy can lead to reactivation of hepatitis 
B in carriers [80]. Before start of chemotherapy, screen-
ing for hepatitis B (HBsAG, anti-HBC) should there-
fore be performed in all patients (LoE 2c/AGO+). If 
one of the tests is positive, HBV DNA needs to be de-
termined. In case of HBV DNA detection, virostatic 
therapy needs to be initiated and chemotherapy inter-
rupted (AGO++).
The essential drug management for antiemetic thera-
py has been revised (https://www.mascc.org). For pa-
tients in the acute and as well in the delayed emetic high-
risk group, olanzapine may be offered on days 1–4, par-
ticularly if nausea is a concern. As sedation and weight 
gain are side effects, a dose reduction from 10 to 5 mg/day 
is a valid option [81, 82].
Chemotherapy-induced peripheral neuropathy is a 
common toxicity following taxane or subsequent 
T-DM1 therapy with an incidence of up to 50% grade 
1–2 and up to 20% grade 3 and 4. Thus, besides continu-
ing measures for neuropathy prevention such as tight 
surgical gloves and compression stockings (LoE 2b/B/
AGO+), cooling gloves and stockings (LoE 2b/B/
AGO+/–) and tactile stimulation (LoE 5/D/AGO+) are 
very important. While drug-based prevention and treat-
ment options are limited (AGO+/–), non-drug-based 
therapy might be an option (AGO+) with functional 
treatment (LoE 2a/C), physiotherapy (LoE 5/D), and 
acupuncture (LoE 2b/B).
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Follow-Up of Breast Cancer
Less intensive follow-up for patients with DCIS (clini-
cal examination all 6 months) versus patients with inva-
sive breast cancer (all 3 months) is recommended.
Still, the rationale of breast cancer follow-up is the ear-
ly detection of curable breast cancer events (LoE 1a/B/
AGO++). Early detection of symptomatic metastases is 
desirable (LoE 3b/C/AGO+); however, with regard to the 
early detection of asymptomatic metastases (LoE 1a/A/
AGO–), data are inconsistent and, most importantly, do 
not suggest a survival benefit.
Beyond improvement of survival, additional issues 
like improvement of quality of life and physical perfor-
mance as well as the reduction and early detection of 
treatment-related side effects are important concerns in 
this matter (LoE 2b/B/AGO+). We added recommenda-
tions on cardiologic workup (echocardiography, BNP 
measurement in selected cases) in patients treated by an-
thracyclines/anti-HER2 agents in the adjuvant situation 
12 and 60 months after therapy completion according to 
international guidelines [83].
In addition, re-evaluation of current adjuvant thera-
pies (including re-evaluation of menopausal status and 
change and/or addition of ovarian suppression in high-
risk premenopausal patients with chemotherapy-induced 
amenorrhea) and the assessment or improvement of treat-
ment adherence is an essential part of follow-up care (LoE 
2b/B/AGO++). Thus, it should be pointed out that every 
patient has the right to obtain a second opinion (LoE 2c/B/
AGO++); genetic counseling should be offered if indicat-
ed, as should hormone replacement therapy, prophylactic 
surgery, and breast reconstruction (LoE 2c/C/AGO+). 
Lifestyle modifications and interventions with regard to 
comorbidities are further important aspects of follow-up.
Most importantly, follow-up examinations of asymp-
tomatic patients in routine situations should not include 
tumor marker measurements or imaging of any kind. For 
the detection of curable events, physical and self-exami-
nation with MG and adjunctive US as well monitoring of 
treatment toxicity (e.g., of endocrine therapy) are recom-
mended. Follow-up of male breast cancer patients should 
follow the same procedures as in female breast cancer pa-
tients (LoE 5/D/AGO+). Unfortunately, there are still no 
data that would support tailoring breast cancer follow-up 
according to molecular subtype.
In case of increased risk such as age <50 years, HR 
negativity, and decreased diagnostic accessibility C/D in 
MG and US, MRI should be considered [84].
In this context, screening for secondary malignancies 
according to guidelines is meaningful. Patients and phy-
sicians should be aware of increased risk of hematologic 
malignancies after chemotherapy and lung cancer after 
radiotherapy to the breast or chest wall. Further, a DXA 
scan at baseline and a repeat scan according to individual 
risk in women with premature ovarian failure or in wom-
en on AI therapy are recommended [85].
Health Literacy and Communication
The options for healthy people and patients in cancer 
prevention and therapy are constantly increasing. At the 
same time, a change has taken place in the healthcare sys-
tem, which strengthens the patients’ right of self-determi-
nation and embodied in law the informed and shared de-
cision-making process between patients and their doc-
tors, who should no longer make decisions on prevention 
and treatment concepts alone.
Healthy people as well as patients should be instructed 
and involved as “experts in their own affairs” during the 
process of preventing and treating cancer. The main focus 
is on enabling a self-determined decision on the basis of 
a sufficient heathy competence (AGO+) and improving 
shared decision-making, which depends on successful 
doctor-patient communication.
Health Literacy
Despite a huge media presence of expert content, it 
seemed to be difficult for the majority of patients to dis-
tinguish between what is really important and how to 
make the right decisions for coping with illness (health 
literacy). According to a current survey from 2017, half of 
all Germans have insufficient or clearly limited health lit-
eracy. As a result, numerous initiatives and offers were 
launched to improve health literacy (Alliance for Health 
Literacy, National Action Plan Health Literacy). They fo-
cus on the special form of doctor-patient relationship and 
are based on an overarching set of values: respect for the 
right of self-determination of the individual, the principle 
of non-harm, care, and equality.
Communication
Good communication skills are a medical core compe-
tence and the basis for a trusting doctor-patient relation-
ship. This in turn has an important influence on the un-
derstanding of the disease as well as on cooperation in 
diagnosis, treatment, and rehabilitation, and thus on the 
success of treatment. “Talking medicine” is becoming in-
creasingly important in the healthcare system (remuner-
ation) and is offered across sectors as a part of training 
and continuing education programs for all healthcare 
professionals. Qualified training measures can help to 
promote communicative skills (AGO+).
Shared Decision-Making and Patient Decision Aids
Successful communication and the development of a 
trustful doctor-patient relationship is an important cor-
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nerstone for patient participation in the shared decision-
making process. The use of decision support in the phy-
sician-patient communication (AGO+) will (a) improve 
knowledge, information, and risk perception about treat-
ment options, (b) reduce the decision conflict, (c) in-
crease the feeling about clarity of personal values, (d) en-
courage an active role in decision-making, and (e) im-
prove the match between the chosen option and the 
patient’s values.
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